文献速递乳腺癌

乳腺癌免疫治疗现状综述

Current Landscape of Immunotherapy in Breast Cancer: A Review.
PubMed 文献 · JAMA Oncol · 2019-01-01

本文综述乳腺癌免疫治疗现状,检索截至2018年6月30日的PubMed及2018年4月24日的ClinicalTrials.gov,发现免疫检查点阻断(ICB)是研究最多的免疫治疗形式;ICB单药在乳腺癌患者中可获得客观缓解,早期治疗线应用时缓解率更高,缓解持久;近期数据显示ICB联合化疗有临床疗效;尚无稳健的预测ICB反应的生物标志物;预期联合治疗策略是未来方向。

要点

  • ICB单药在乳腺癌中可获得客观缓解,早期治疗线应用时缓解率更高,缓解持久。
  • 近期数据显示ICB联合化疗具有临床疗效。
  • 尚无稳健的预测ICB反应的生物标志物。

核心结论

  • 预期联合治疗策略将是乳腺癌免疫治疗的前进方向,对肿瘤、微环境和宿主因素的深入理解将指导治疗联合决策。
  • 精心设计的研究方案纳入合适终点和转化研究,对确定增强抗肿瘤免疫应答的最佳策略至关重要。

研究设计与样本

  • 叙述性综述,检索ClinicalTrials.gov(2018年4月24日)和PubMed(截至2018年6月30日)以识别乳腺癌免疫治疗试验。
  • 综述时正在进行的临床试验超过290项。

主要发现

  • 免疫检查点阻断(ICB)是乳腺癌中研究最多的免疫治疗形式。
  • ICB单药在乳腺癌患者中已获得客观缓解,早期治疗线应用时缓解率更高。
  • 对缓解的患者,缓解持久。
  • 近期数据提示ICB联合化疗具有临床疗效。
  • 正在开展的研究评估ICB联合其他化疗药物、靶向治疗、疫苗和局部消融治疗以增强缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. OBSERVATIONS: After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. CONCLUSIONS AND RELEVANCE: It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Adams S, Gatti-Mays ME, Kalinsky K, et al. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. 2019. PMID: 30973611. doi:10.1001/jamaoncol.2018.7147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。